Joseph Schwartz
Stock Analyst at Leerink Partners
(3.13)
# 1,118
Out of 4,870 analysts
141
Total ratings
31.3%
Success rate
16.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $100 → $115 | $105.42 | +9.09% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $7.18 | +67.25% | 4 | May 23, 2025 | |
| RGLS Regulus Therapeutics | Downgrades: Market Perform | $7 | $8.14 | -14.00% | 3 | Apr 30, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $10.73 | +160.95% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $14.49 | +176.05% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.30 | +4,566.67% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.07 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $4.51 | +166.08% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.74 | +191.97% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.20 | -16.67% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $3.90 | +53.85% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $49.60 | -3.23% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $17.42 | +3.33% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $11.93 | +67.64% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $37.67 | -9.74% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $54.08 | +140.38% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $18.87 | +747.91% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $175.79 | -7.28% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.37 | +629.93% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.39 | +2,274.10% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $7.83 | +53.26% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $36.83 | +193.24% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $29.91 | +30.39% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $0.79 | +404.41% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $14.18 | +111.57% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $29.15 | +71.53% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $53.30 | -43.71% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $13.95 | +301.43% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.71 | +145.18% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.95 | +515.38% | 2 | Sep 26, 2017 |
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $105.42
Upside: +9.09%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $7.18
Upside: +67.25%
Regulus Therapeutics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $7
Current: $8.14
Upside: -14.00%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $10.73
Upside: +160.95%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $14.49
Upside: +176.05%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.30
Upside: +4,566.67%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.07
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $4.51
Upside: +166.08%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.74
Upside: +191.97%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.20
Upside: -16.67%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.90
Upside: +53.85%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $49.60
Upside: -3.23%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $17.42
Upside: +3.33%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $11.93
Upside: +67.64%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $37.67
Upside: -9.74%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $54.08
Upside: +140.38%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $18.87
Upside: +747.91%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $175.79
Upside: -7.28%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.37
Upside: +629.93%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.39
Upside: +2,274.10%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $7.83
Upside: +53.26%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $36.83
Upside: +193.24%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $29.91
Upside: +30.39%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $0.79
Upside: +404.41%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $14.18
Upside: +111.57%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $29.15
Upside: +71.53%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $53.30
Upside: -43.71%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $13.95
Upside: +301.43%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $5.71
Upside: +145.18%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.95
Upside: +515.38%